October 19, 2026

Tempus Presents Data Demonstrating AI-Enabled Pre-Screening Can Help Identify Patients for Biomarker Testing in NSCLC

Tempus: Study presented at ESMO evaluated more than 60,000 advanced NSCLC cases and found greater than 80% sensitivity across all 12 biomarkers using routine H&E pathology images CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today...

recent articles

Do you want to learn how to fine-tune your APP? Join Michael Persch, a Professional Services Specialist, and learn how adjustable parameters in VIS can dramatically affect your APP's performance and execution speed. Tune into the next...

In the wake of the 9/11 terrorist attacks on our country, by the following Tuesday anthrax spores were discovered in letters mailed to members of the media and United States senate. Subsequently, additional cases were discovered and the United...

As the world begins to see positive results in our collective efforts to “flatten the curve” of COVID-19 infections, Inspirata aims to bring light to what a post-pandemic world would look like for the pathology profession. Tampa, Florida...

Press Release | VISTA, CA April 24, 2020 – Leica Biosystems, the global leader in pathology workflow solutions, today announced it has received additional notification from the U.S. Food & Drug Administration (FDA) about its intention to...

Feedbacks from hospitals in France, Canada and Belgium Dowload the White Paper Contents Many surgical procedures are being cancelled in this time of crisis, however cancer care must continue. Furthermore, cancer / COVID-19...

OR

platinum partners

gold partners

Silver Partners

Media Partners